Hologic price target raised to $95 from $89 at Argus

Argus raised the firm’s price target on Hologic to $95 from $89 and keeps a Buy rating on the shares. The company delivered “strong” Q2 results and raised the midpoint of guidance for FY24, also offering a strong balance sheet and solid cash flow generation, the analyst tells investors in a research note. Argus sees higher non-COVID diagnostic volume and higher elective procedural volume driving revenue growth in FY24 for Hologic.